These innovative drugmakers have potential catalysts ahead.Once a company's shares rise rapidly, investors might wonder if it's still worth investing in the stock. The answer is that it depends. Some companies' strong performances are short-lived. Others perform well because they have attractive businesses that can deliver outsized returns in the long run. Those in the second category are worth investing in even after an impressive run.Let's look at two examples: Eli Lilly (LLY 1.34%) and Sarepta Therapeuti ...